K-BASKET, TAS-117, PI3K/AKT Gene Aberration

NCT ID: NCT03017521

Last Updated: 2021-04-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-21
• Study Completion Date: 2019-12-31

Brief Summary

The phosphatidylinositol 3-kinase (PI3K)-v-akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) signaling pathway is one of the most frequently aberrantly regulated pathways in human tumors. TAS-117 is a highly potent and selective oral allosteric AKT inhibitor. It has high affinity for AKT1, 2, and 3 and shows potent anti-proliferative activity against multiple tumor cell lines in vivo. Therefore, we propose to conduct a phase II trial of TAS-117, potent and selective AKT inhibitor, in patients with advanced solid tumor with PI3K/AKT genetic aberrancy by NGS focusing panel in part of K-BASKET trial.

Conditions

Solid Tumor, Adult

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TAS-117

TAS-117, 16mg, orally, daily

Group Type: EXPERIMENTAL

TAS-117

Intervention Type: DRUG

TAS-117 16mg, daily

Interventions

TAS-117

TAS-117 16mg, daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically or cytologically confirmed recurrent or advanced solid cancers with PI3K/ATK aberration

2. Progressive disease who failed to previous standard treatment.

3. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria

4. Eastern Cooperative Oncology Group performance status 0 or 1

5. Able to take medications orally

6. Adequate organ function

7. A life expectancy of at least 60 days

Exclusion Criteria

1. Previous treatment with anti-PI3K or AKT directed therapies

2. Known hypersensitivity to any drugs similar to TAS-117 in structure or class.

3. History or current evidence of type 1 or type 2 diabetes mellitus that requires insulin and/or oral antidiabetic therapy.

4. Current evidence of retinopathy that requires ophthalmological therapy.

5. History or current evidence of cardiac arrhythmia and/or conduction abnormality.

6. Treatment with any of the following within the specified time frame prior to study drug administration:

• Major surgery within prior 4 weeks
• Radiation therapy for extended field within 4 weeks prior to study drug administration or limited field radiation therapy within 2 weeks prior to study drug administration.
• Any anticancer treatment within 3 weeks prior to study drug administration (mitomycin within prior 5 weeks).

7. A serious illness or medical condition(s)

8. Unresolved toxicity of Grade >1 attributed to any prior therapies (excluding alopecia, skin pigmentation and anemia).

9. Patients with the risk of hypokalemia

10. Receiving oral steroid medication.

11. Pregnant or lactating female

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yonsei University

OTHER

Sponsor Role: lead

Responsible Party

Minkyu Jung

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Countries

South Korea

References

Lee JB, Jung M, Beom SH, Kim GM, Kim HR, Choi HJ, Sohn JH, Ahn JB, Rha SY, Chung HC. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. Invest New Drugs. 2021 Oct;39(5):1366-1374. doi: 10.1007/s10637-021-01085-7. Epub 2021 Mar 15.

Reference Type: DERIVED

PMID: 33723724 (View on PubMed)

Other Identifiers

4-2016-0743

Identifier Type: -

Identifier Source: org_study_id